Skip to main content

Advertisement

Table 2 Characteristics of the 33 trials with adequate reporting of serious adverse events

From: Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles

Characteristic n (%)
n = 33
Study phase
 III 29 (88)
 IV 4 (12)
Study design
 Parallel groups 31 (94)
 Cross-over 2 (6)
No. of intervention groups
 2 30 (91)
 3 3 (9)
Primary funding source
 Industry 27 (82)
 US National Institutes of Health 2 (6)
 US federal funding 1 (3)
 Other 3 (9)
Medical condition
 Endocrinology 6 (18)
 Infectious diseases 4 (12)
 Cardiology 3 (9)
 Gynecology 3 (9)
 Neurology 3 (9)
 Rheumatology 3 (9)
 Psychiatry 3 (9)
 Other 8 (24)
Study location
 At least one site in the United States 24 (73)
 No site in the United States 9 (27)
Type of journal
 Specialty 24 (73)
 General 9 (27)
ClinicalTrials.gov NCT reported in article
 Yes 27 (82)
 No 6 (18)